PR3-AAV Resilient Remission or PRRR

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

PR3-AAV Resilient Remission or PRRR

Official Title

A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Brief Summary

      The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the
      treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Study Phase

Phase 2

Study Type


Primary Outcome

Number of patients to achieve both complete remission and seronegativity for ANCA.

Secondary Outcome

 Number of patients to achieve sustained complete remission 6 months


Granulomatosis With Polyangiitis



Study Arms / Comparison Groups

 Intravenous dose of obinutuzumab
Description:  Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of obinutuzumab


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 2022

Completion Date

July 2024

Primary Completion Date

January 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Fulfillment of the definitions of the Second Chapel Hill Consensus Conference for
             ANCA-associated vasculitis (either granulomatosis with polyangiitis or microscopic

          -  Positivity for ANCA, directed against proteinase-3 (PR3)

          -  Severe newly-diagnosed disease or severe relapsing disease. Severe relapsing disease
             is defined as at least one major BVAS/WG item or a score ≥ 3 and the investigator
             deems standard treatment for severe disease is necessary.

          -  Minimum BVAS/WG of 3

          -  Relapsing patients must have B cells detectable in the peripheral blood.

          -  Patients must have completed COVID19 vaccination (including booster if eligible) at
             least 4 weeks prior to enrollment with a positive spike protein antibody test result.
             Patients who have recovered from COVID19 prior to screening with a positive spike
             protein antibody test result but have not been vaccinated are also eligible.

          -  Female subjects of childbearing potential who are not sterile must agree to use an
             acceptable method of contraception for 18 months after the last dose of infusion
             medication. Male subjects who are not sterile whose female partners are of
             childbearing potential must agree to use an acceptable method of contraception for 180
             days after the last dose of infusion medication.

               -  Females of childbearing potential include any female who has not undergone
                  successful surgical sterilization (hysterectomy, bilateral tubal ligation, or
                  bilateral oophorectomy) or is not postmenopausal (to be considered
                  postmenopausal, the patient must have had amenorrhea for >12 consecutive months).

               -  Acceptable methods of contraception include the use of at least two of the
                  following: 1) intrauterine device; 2) hormonal contraceptives for at least 30
                  days prior to first dose infusion (oral, injectable, implant or ring); 3) barrier
                  contraceptives (condom or diaphragm) with spermicide; or 4) abstinence.

        Exclusion Criteria:

          -  Diagnosis with eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss
             syndrome) as defined by the Chapel Hill Consensus Conference.

          -  Positive serum assays for ANCA directed against myeloperoxidase (MPO-ANCA)

          -  Non-severe AAV, defined as disease that does not justify treatment with both B cell
             depletion and a four-month glucocorticoid taper.

          -  Any of the co-morbidities:

               -  Allergies: a history of severe allergic reactions to human or chimeric monoclonal
                  antibodies or murine protein.

               -  Infection (systemic): an active systemic infection at screening visit

               -  Infection (deep space): have been diagnosed as having a deep-space infection,
                  such as osteomyelitis, septic arthritis, or pneumonia complicated by empyema or
                  lung abscesses, within 6 months prior to the screening visit

               -  Infection (blood borne): active hepatitis B or active hepatitis C or a documented
                  history of HIV, hepatitis B, or hepatitis C

               -  Infection (history): History of recurrent significant infection or history of
                  recurrent bacterial infections

               -  Liver disease: acute or chronic liver disease that is deemed sufficiently severe
                  to impair their ability to participate in the trial.

               -  Renal disease: a history of documented anti-glomerular basement membrane disease
                  (anti-GBM disease).

               -  Malignancy: Active or history of malignancy in the last 5 years. Individuals with
                  squamous cell or basal cell skin carcinomas and individuals with cervical
                  carcinoma in situ may be enrolled if they have received curative surgical

               -  Active COVID-19 infection.

               -  Uncontrolled disease: evidence of glucocorticoid dependent disease (such as
                  asthma, COPD, psoriasis or IBD, etc.) requiring consistently greater than 10 mg
                  of prednisone for disease control which might affect endpoint assessment or,

               -  Other uncontrolled diseases, including any uncontrolled psychiatric disorders,
                  drug and alcohol abuse, that could interfere with participation in the trial
                  according to the protocol.

          -  Diagnosis of human anti-chimeric antibodies (HACA) formation.

          -  Subjects who are premenopausal and are:

               -  Pregnant on the basis of a serum pregnancy test,

               -  Breastfeeding, or

               -  Do not agree to use effective method(s) of contraception

          -  Use of prohibited medications: They have used any of the prohibited medication listed
             in Section 5.9.1.

          -  Plasma exchange: They have been treated with plasma exchange within the 3 months
             preceding the screening visit.

          -  History of intolerance to rituximab or other chimeric monoclonal antibodies (e.g.,

          -  Recent vaccination: They have had a live vaccine fewer than 4 weeks (28 days) before
             or during randomization (vaccination with live vaccine through the end of study
             participation is contraindicated).

          -  Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Exclusion criteria related to laboratory parameters:

               -  Bone marrow suppression as evidenced by a total white count < 4 x10 /l,
                  hemoglobin < 7 gm/dl or platelet count < 100,000/μl

               -  Aspartate aminotransferase or alanine aminotransferase or amylase > 2.5 times the
                  upper limit of normal, unless attributed to vasculitis




18 Years - N/A

Accepts Healthy Volunteers



Ulrich Specks, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Mayo Clinic

Study Sponsor

Ulrich Specks, MD, Principal Investigator, Mayo Clinic

Verification Date

May 2022